These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8050449)

  • 1. European Study Group on Antibiotic Breakpoints. Breakpoint determination: sparfloxacin.
    Phillips I; Acar J; Baquero F; Bergan T; Degener J; Forsgren A; Schito GC; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1994 Mar; 13(3):283-4. PubMed ID: 8050449
    [No Abstract]   [Full Text] [Related]  

  • 2. ESGAB breakpoint determination: temafloxacin.
    Phillips I; Acar J; Baquero F; Bergan T; Forsgren A; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):991-2. PubMed ID: 1665417
    [No Abstract]   [Full Text] [Related]  

  • 3. European Study Group on Antibiotic Breakpoints. Breakpoint determination: cefepime.
    Phillips I; Acar J; Bergan T; Degener J; Schito GC
    Eur J Clin Microbiol Infect Dis; 1994 Mar; 13(3):282-3. PubMed ID: 8050448
    [No Abstract]   [Full Text] [Related]  

  • 4. Breakpoint determination: rufloxacin.
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):574-5. PubMed ID: 8404928
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial clinical experience with clinafloxacin in the treatment of serious infections.
    Tack KJ; McGuire NM; Eiseman IA
    Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411
    [No Abstract]   [Full Text] [Related]  

  • 8. Sparfloxacin and other new fluoroquinolones.
    Richard P; Gutmann L
    J Antimicrob Chemother; 1992 Dec; 30(6):739-44. PubMed ID: 1337749
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
    Richard MP; Aguado AG; Mattina R; Marre R
    J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Review [new antimicrobial agent series XLI]: lomefloxacin].
    Soejima R; Matsumoto F
    Jpn J Antibiot; 1991 Oct; 44(10):1045-60. PubMed ID: 1662290
    [No Abstract]   [Full Text] [Related]  

  • 11. [The dose-response study of sparfloxacin against skin and soft tissue structure infections in the field of surgery].
    Nakayama I; Yamaji E; Kawamura H; Kawaguchi H; Akieda Y; Suzuki T; Watanabe T; Itokawa K
    Jpn J Antibiot; 1993 Aug; 46(8):706-25. PubMed ID: 8230738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinolones in dermatology.
    Sable D; Murakawa GJ
    Dis Mon; 2004 Jul; 50(7):381-94. PubMed ID: 15280869
    [No Abstract]   [Full Text] [Related]  

  • 13. [Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].
    Jpn J Antibiot; 1994 Oct; 47(10):1241-58. PubMed ID: 7807686
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of resistance to fluoroquinolones among bacteria causing infections in food animals in Denmark.
    Aarestrup FM; Jensen NE; Jorsal SE; Nielsen TK
    Vet Rec; 2000 Jan; 146(3):76-8. PubMed ID: 10674696
    [No Abstract]   [Full Text] [Related]  

  • 15. The ocular penetration of oral sparfloxacin in humans.
    Bron AM; Pechinot AP; Garcher CP; Guyonnet GA; Kazmierczak AM; Schott DA; Lecoeur H
    Am J Ophthalmol; 1994 Mar; 117(3):322-7. PubMed ID: 8129004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New uses for new and old quinolones and the challenge of resistance.
    Hooper DC
    Clin Infect Dis; 2000 Feb; 30(2):243-54. PubMed ID: 10671323
    [No Abstract]   [Full Text] [Related]  

  • 17. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
    Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bactericidal activity of quinolones (including sparfloxacin) against Enterococcus; in vitro antagonisms with gentamicin].
    Watine J; Charet JC
    Pathol Biol (Paris); 1997 May; 45(5):430-2. PubMed ID: 9296098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European standards for antibiotic susceptibility testing: towards a theoretical consensus.
    Baquero F
    Eur J Clin Microbiol Infect Dis; 1990 Jul; 9(7):492-5. PubMed ID: 2226478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.